SG Americas Securities
KZR

SG Americas Securities’s Kezar Life Sciences KZR Stock Holding History

SG Americas Securities’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,462
Closed -$22K – 3086
2024
Q1 		$22K Sell
2,462
-1,933
-44% -$17.6K ﹤0.01% 2853
2023
Q4 		$42K Buy
4,395
+1,111
+34% +$9.77K ﹤0.01% 2944
2023
Q3 		$39K Buy
+3,284
New +$58.2K ﹤0.01% 2980
2023
Q2 		– Sell
-2,134
Closed -$67K – 2751
2023
Q1 		$67K Buy
2,134
+218
+11% +$12.6K ﹤0.01% 3017
2022
Q4 		$135K Buy
1,916
+146
+8% +$10.8K ﹤0.01% 2509
2022
Q3 		$152K Sell
1,770
-47
-3% -$4.57K ﹤0.01% 2540
2022
Q2 		$150K Buy
1,817
+1,045
+135% +$92.2K ﹤0.01% 2870
2022
Q1 		$128K Sell
772
-26,989
-97% -$3.87M ﹤0.01% 2667
2021
Q4 		$4.64M Buy
27,761
+25,413
+1,082% +$2.87M 0.03% 535
2021
Q3 		$203K Buy
+2,348
New +$155K ﹤0.01% 3230
2020
Q3 		– Sell
-1,420
Closed -$74K – 3095
2020
Q2 		$74K Buy
1,420
+341
+32% +$17.2K ﹤0.01% 3459
2020
Q1 		$47K Buy
+1,079
New +$43.9K ﹤0.01% 3188

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SG Americas Securities's KZR Position: Q2 2024 in Review

SG Americas Securities sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 2,462 shares — an estimated $22K sold.

SG Americas Securities first reported a position in KZR in Q1 2020 and held it in 12 quarters. The position peaked at $4.64M in Q4 2021. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • SG Americas Securities reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 2,462 Kezar Life Sciences shares in Q2 2024, an estimated $22K.
  • SG Americas Securities first reported a position in Kezar Life Sciences in Q1 2020 and held it in 12 quarters.
  • SG Americas Securities's Kezar Life Sciences position peaked at $4.64M in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.